The staggering failure rate of drugs in human trials, despite promising animal studies, has sparked a revolution in drug development. With over 90% of drugs failing to translate from animals to humans, the pharmaceutical industry is rethinking its approach.
The Future of Drug Development: Beyond Animal Testing
Animal testing, while a cornerstone of drug development, is facing increasing scrutiny due to its limitations. Even minor variations in how different species process drugs can lead to drastically different outcomes, highlighting the need for more accurate and humane methods.
Recent examples, such as the discontinuation of vupanorsen and ziritaxestat, and the fatal failures of BMS-986094, demonstrate the urgent need for change. These cases are not anomalies; they emphasize the persistent gap between preclinical and clinical safety assessments.
Clinical trial data reveals that drug failures are often due to a lack of efficacy or unmanageable toxicity in humans. Species differences and the inability of animal models to capture the complexity of human diseases are at the heart of these issues.
But here's where it gets controversial: animal studies still have a role, but it's a smaller one. They remain useful for understanding certain immune responses and behavioral outcomes. However, the focus is shifting towards technologies that can better predict human responses, especially in areas like liver toxicity and pharmacokinetics.
The FDA's recent announcement to phase out animal testing requirements for monoclonal antibodies is a significant step towards more human-centric models. One promising alternative is the use of donated human organs that cannot be transplanted for research purposes.
The Promise of Human Organ Testing
Advances in organ perfusion technology allow researchers to maintain donated organs in a living state, creating a unique platform for drug testing. Perfused human organs offer physiological responses that are likely to be more accurate, capturing subtle metabolic and toxicological pathways that animal models miss.
The ability to sample and observe responses more frequently and invasively provides early warning signals, potentially preventing damage before it occurs. Organs like the liver, kidney, heart, and lungs are particularly promising due to well-developed perfusion systems in transplantation medicine.
Contrary to popular belief, research organs are not always "too damaged" to be useful. Many are declined for transplantation due to factors unrelated to their scientific value, and in fact, organs reflecting common patient conditions can make research findings more representative.
The process involves redirecting donated organs for research with full consent, transporting them under clinical preservation systems, and quickly preparing them for perfusion. Once connected to a perfusion machine, the organ is kept alive, allowing researchers to administer drug candidates and monitor responses in real-time.
Ethical safeguards are crucial, ensuring data is de-identified and protecting confidentiality. The goal is to ensure research reflects the diversity of patient populations and ultimately benefits everyone. This approach also honors the wishes of donors and their families who want to contribute altruistically.
As with living patients, scientists observe variations between organs, which can initially be challenging to interpret. However, these differences mirror the heterogeneity seen in patients, providing an opportunity to understand individual biology and treatment responses.
A Shift in Perspective
Regulators and industry leaders are embracing change. The US FDA is phasing out certain animal testing requirements, and Congress has passed the FDA Modernization Act 3.0 to accelerate this transition. The National Institutes of Health is also prioritizing human-based research technologies.
For pharmaceutical companies, integrating human organ data with other streams can provide a more complete understanding of human biology before costly First in Human Trials. This approach complements animal data, placing it within a broader, human-centric framework.
Patients stand to benefit significantly, with fewer failed trials leading to more therapies reaching the market faster. Every averted failure means not only financial savings but also years of suffering avoided.
The Future of Drug Development
The future of drug development is likely to involve a convergence of technologies, including perfused human organs, organs-on-chips, 3D bioprinting, and multi-omics data streams, integrated by artificial intelligence. Machine learning's ability to unify datasets promises insights into human physiology that were previously inaccessible.
For this vision to become standard practice, innovators must demonstrate the reproducibility and reliability of these technologies, and regulators must provide clear pathways for qualification and acceptance. Progress is already underway, with regulators publishing guidance and creating qualification programs.
Looking ahead, animal models will likely continue in a reduced capacity, used selectively for their specific strengths. Human-relevant technologies are expected to become the foundation of development pipelines, offering faster timelines and improved translational accuracy.
The 90% failure rate is not an inevitability but a challenge to be overcome. Human organ testing, alongside complementary technologies, offers a way to align drug development more closely with human biology.
The shift is happening, driven by scientific advances, regulatory support, and patient demand. What was once unthinkable is now seen as the path forward, leading to safer, faster, and more effective therapies.
